Novartis Teams Up With Legend, Moving CAR-T Into Solid Tumors
The Swiss drug maker is licensing multiple DLL3-targeting CAR-Ts from the Chinese biotech, including one already in early clinical development, and will use its T-Charge manufacturing platform.
You may also be interested in...
Plus deals involving Abliva/Owl, Selecta/Cartesian, Novo Nordisk/Genevant, AbbVie/Aldeyra and more.
An exec told the company’s Q3 earnings call it was “surprising” that cell therapy adoption for LBCL remains around only 10% of eligible patients despite Yescarta producing strong clinical data.
Amgen's DLL3-targeting bispecific T-cell engager could be filed on Phase II data having demonstrated exceptional duration of response in small cell lung cancer patients.